Delve into the increasingly dynamic landscape of ALS treatment development with thirteen companies advancing candidates in ...

With the hold lifted, Amylyx can begin screening and enrolling for its Phase 1 LUMINA trial, which will test AMX0114 in ALS ...

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that remains incurable, despite decades of basic and clinical research. Key stakeholders—including the US National ...

The ALS Association will host its second ALS Nexus conference in August, with the goal of making the disease a livable one ...

This is the latest venture for Amylyx into the ALS field after its previous therapy Relyvrio was pulled from the market in ...

Joseph Smith, 71, and others stole more than $450,000 in disability benefits from the man between roughly 2015 and 2020, when ...

CAMBRIDGE, Mass. - Amylyx Pharmaceuticals Inc. (NASDAQ: AMLX), a $245.1 million market cap biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical ...

I felt the fragility of life for the first time and I had to look at what it meant to lose someone you love. The experience ...

Introduction: T regulatory cells (Tregs) inversely correlate with disease progression in Amyotrophic Lateral Sclerosis (ALS) and fast-progressing ALS patients have been reported to exhibit ...

Early signs of multiple sclerosis can include blurry vision, muscle weakness, dizziness and fatigue, and unusual tingling or pain sensations. These early warning signs occur because of damage to the ...

usa.net Background Different amyotrophic lateral sclerosis (ALS) phenotypes have been recognised, marked by a varying involvement of spinal and bulbar upper and lower motor neurons. However, the ...